Evidence map›Paper›PMID 39023560›Full record

ArticleCellular and molecular life sciences : CMLS2024

Cryopreservation of human kidney organoids.

Parham Mashouf, Nahid Tabibzadeh, Shohei Kuraoka, Haruka Oishi, Ryuji Morizane

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Organoids in disease modeling and regenerative medicine.Cellular and molecular life sciences : CMLS · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Parham MashoufNephrology Division, Department of Medicine, Massachusetts General Hospital, 149 13th Street, Boston, MA, 02129, USA.
Nahid TabibzadehNephrology Division, Department of Medicine, Massachusetts General Hospital, 149 13th Street, Boston, MA, 02129, USA.
Shohei KuraokaNephrology Division, Department of Medicine, Massachusetts General Hospital, 149 13th Street, Boston, MA, 02129, USA.
Haruka OishiNephrology Division, Department of Medicine, Massachusetts General Hospital, 149 13th Street, Boston, MA, 02129, USA.
Ryuji MorizaneNephrology Division, Department of Medicine, Massachusetts General Hospital, 149 13th Street, Boston, MA, 02129, USA. rmorizane@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-0377-5667

Funding

Ex Vivo Generation of Functional Kidney Tissues for TransplantationUC2DK126023 · NIDDK · HARVARD UNIVERSITY · PI LEWIS, JENNIFER A. · 2020 to 2024
$4.0M
Recreating Kidney Organogenesis in vitro with Human Pluripotent Stem CellsDP2DK133821 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MORIZANE, RYUJI · 2019 to 2019
$2.5M
Vascularized kidney organoids on chip for efficacy and toxicity testing of somatic genome editingU01DK127587 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI LEWIS, JENNIFER A., MORIZANE, RYUJI · 2020 to 2022
$2.1M
Vascularized kidney organoids on chip for efficacy and toxicity testing of somatic genome editingU01EB028899 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI LEWIS, JENNIFER A., MORIZANE, RYUJI · 2019 to 2019
$748k
Development of a fluidic chip model of PKD to elucidate cystogenic signals using kidney organoidsR21DK129909 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MORIZANE, RYUJI · 2022 to 2022
$216k
NIBIB NIH HHS U01 EB028899NIDDK NIH HHS DK126023NIDDK NIH HHS DK127587NIDDK NIH HHS DK133821NIDDK NIH HHS DP2 DK133821NIDDK NIH HHS R21 DK129909NIDDK NIH HHS U01 DK127587NIDDK NIH HHS UC2 DK126023
6 · The paper itself

Abstract

Recent advances in stem cell research have led to the creation of organoids, miniature replicas of human organs, offering innovative avenues for studying diseases. Kidney organoids, with their ability to replicate complex renal structures, provide a novel platform for investigating kidney diseases and assessing drug efficacy, albeit hindered by labor-intensive generation and batch variations, highlighting the need for tailored cryopreservation methods to enable widespread utilization. Here, we evaluated cryopreservation strategies for kidney organoids by contrasting slow-freezing and vitrification methods. 118 kidney organoids were categorized into five conditions. Control organoids followed standard culture, while two slow-freezing groups used 10% DMSO (SF1) or commercial freezing media (SF2). Vitrification involved V1 (20% DMSO, 20% Ethylene Glycol with sucrose) and V2 (15% DMSO, 15% Ethylene Glycol). Assessment of viability, functionality, and structural integrity post-thawing revealed notable differences. Vitrification, particularly V1, exhibited superior viability (91% for V1, 26% for V2, 79% for SF1, and 83% for SF2 compared to 99.4% in controls). 3D imaging highlighted distinct nephron segments among groups, emphasizing V1's efficacy in preserving both podocytes and tubules in kidney organoids. Cisplatin-induced injury revealed a significant reduction in regenerative capacities in organoids cryopreserved by flow-freezing methods, while the V1 method did not show statistical significance compared to the unfrozen controls. This study underscores vitrification, especially with high concentrations of cryoprotectants, as an effective approach for maintaining kidney organoid viability and structure during cryopreservation, offering practical approaches for kidney organoid research.

Indexed as

CryopreservationCryoprotective AgentsKidneyOrganoidsCell SurvivalDimethyl SulfoxideEthylene GlycolFreezingHumansVitrificationCryoprotective AgentsDimethyl SulfoxideEthylene GlycolCryopreservationDimethyl sulfoxideFreezingKidneyOrganoidsVitrification

Identifiers

PMID39023560
PMCPMC11335230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.